S
SAB Biotherapeutics, Inc. (SABS)
NCM – Real Time Price. Currency in USD
3.80
-0.07 (-1.81%)
At close: Jun 26, 2026, 4:00 PM EDT
3.81
+0.01 (0.34%)
After-hours: Jun 26, 2026, 7:14 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
3.80
-0.07 (-1.81%)
At close: Jun 26, 2026, 4:00 PM EDT
3.81
+0.01 (0.34%)
After-hours: Jun 26, 2026, 7:14 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $20.5M significantly exceed its total debt $6.2M, ensuring strong financial flexibility
Total current assets $112.8M exceed Total current liabilities $9.9M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-318.7x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$15.3M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 11.45 | 6.05 | 10 | |
| Quick ratio | 11.45 | 5.63 | 10 | |
| Debt to Equity | 0.03 | 0.30 | 9.0 | |
| Debt to Assets | 0.02 | 1.04 | 9.0 | |
| Interest coverage | -318.71 | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 24M | 2M | 1M | N/A | N/A |
| Gross Profit | 21M | -2M | -3M | -3M | -3M |
| Operating Income | -29M | -38M | -43M | -49M | -58M |
| Net Income | -19M | -42M | -34M | 4M | -26M |
| EBITDA | -26M | -34M | -38M | -46M | -55M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 75.29 | 5.5 |
| Next quarter | N/A | -23.64 | 1.0 |
| Current year | N/A | -22.2 | 1.0 |
| Next year | N/A | 31.34 | 5.5 |
| Weighted average score | 3.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -563.12 | -29.62 | 13.87 | 5.0 |
| Y/Y | 999 | -263.08 | 37.5 | -95.63 | 5.5 |
| 3y average | -77.17 | 2.18 | 17.57 | -22.51 | 3.5 |
| 5y average | 141.35 | -37.59 | 21.11 | -96.41 | 5.5 |
| Weighted average score | 4.9 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |